Regulatory snapshots, including drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations in Asia-Pacific, including: AB Science, Appili, Arch Biopartners, Ascentage, Astrazeneca, Bellerophon, Bridge, Canbridge, Cynata, Daiichi Sankyo, Diffusion, Evelo, Gilead Sciences, Junshi Biosciences, Laurent, Organicell Regenerative, Pluristem, Pulmotect, Redhill, Relief, Takeda, Twi, Zia Lab.

Clinical updates from Asia, including trial initiations, enrollment status and data readouts and publications, including: Athersys, Biontech, Calcimedica, Cytodyn, Daewoong, Eli Lilly, Enlivex, Hightide, Humanigen, Innovent Biologics, Kiniksa, Mesoblast, Noxopharm, Pfizer, Rising.

Biopharma happenings in Asia-Pacific, such as deals and partnerships, grants, preclinical data and other news in brief, including: Adma Biologics, AI Vivo, Altum, Amgen, Antengene, Arcturus, ARTMS Products, Aum Biotech, Aum Lifetech, Beroni Group, Betterlife, Bio Science, Biopharma Plasma, Burning Rock, Certara, Cipla, Cocrystal, Cohbar, Dongwha, Fortebio Analytics, GC Pharma, Gilead Sciences, Idbiologics, Illumina, Innovation, Karyopharm, Lineage Cell, Molecular Partners, Montreal Heart Institute, Noveome, Ose Immunotherapeutics, Predictive Oncology, Proteogenix, Sanquin, Sinovac, Soluble, Sorrento, Sosei Heptares, Telix, Tetra Bio-Pharma, Themis, Tianjin University, Tonix, Vanderbilt University Medical Center, Vaxil Bio, Wuhan University, Zyus Life Sciences.

Biopharmas in Asia-Pacific raising money in public or private financings, including: Bergenbio, Hummingbird Bioscience, Pluristem.

Quarterly snapshots from biopharma companies with marketed products, including: Dynavax Technologies.

BioWorld Asia briefs for May 5.

New hires and promotions in the biopharma industry in Asia-Pacific, including: Tessa Therapeutics.

The activity of many proteins is controlled through phosphorylation by kinases and dephosphorylation by phosphatases.